BridgeBio Oncology Therapeutics, Inc. Common Stock

Day range

$2.61 – $2.68

Open

$2.66

Prev close

$2.66

Volume

279.1K

Market cap

$213.26M

Shares out

80.17M

P/E

—

P/S

—

P/B

0.66

P/FCF

—

ROE

-56.4%

ROA

-48.3%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Business updateSep 8, 2026

  On September 8, 2026, BridgeBio Oncology Therapeutics, Inc. issued a press release titled “BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers.”

• Annual meeting resultsJun 22, 2026

  The proposals set forth below were submitted to the stockholders at the Annual Meeting held on June 16, 2026... Proposal 1 - Election of Directors. The Company's stockholders elected the two (2) director nominees below to the Company's Board of Directors as Class I directors... Proposal 2 - Ratification of Appointment of Independent Registered Accounting Firm. The Company's stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026.

• Executive compensation changeApr 29, 2026

  On April 27, 2026, the Company entered into a consulting agreement with Dr. Wallace, pursuant to which Dr. Wallace will provide the Company with advisory services. Dr. Wallace's exclusive compensation under the Consulting Agreement will be the continued vesting of the outstanding equity awards that he held as of the Effective Date, and Dr. Wallace is entitled to receive the severance benefits applicable to a Tier 1 officer.

• Executive officer appointmentApr 23, 2026

  On April 20, 2026, the Board appointed Neil Kumar, Ph.D., as Executive Chairman of the Board, effective immediately.

• Equity compensation grantMar 26, 2026

  Dr. Lebowitz will receive compensation for his services as a non-employee director and for any committee service in accordance with the Company's amended and restated non-employee director compensation policy, including the automatic grant of a one-time nonqualified stock option under the Company's 2025 Stock Option and Incentive Plan to purchase 63,350 shares of the Company's common stock, $0.0001 par value per share at an exercise price per share equal to $8.72 per share, the closing price on the Nasdaq Global Market on March 24, 2026.

Days to cover

5.4

Short interest

3.37M

Avg volume

624.66K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS)
  positiveGlobeNewswire Inc.· Oct 30, 2025
• Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Kα Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hyperglycemia
  positiveGlobeNewswire Inc.· Oct 25, 2025
• BBOT to Participate in Upcoming September Investor Healthcare Conferences
  positiveGlobeNewswire Inc.· Aug 20, 2025